Biomarker composition for predicting efficacy of tuberculosis vaccine comprising CCL5 and use thereof

Abstract

The present invention relates to a method for predicting efficacy of a tuberculosis vaccine comprising CCL5, in which the CCL5 mediates an immune response induced by administration of a tuberculosis vaccine and exhibits increased expression levels in activated immune cells. Accordingly, by measuring expression levels of a CCL5 protein or a gene encoding the same, prediction accuracy for efficacy or protective immunity of a tuberculosis vaccine can be increased, thereby enabling rapid evaluation of vaccine efficacy, and thus the method can be usefully used in the medical field related to tuberculosis vaccines.

Dependencies are inferred from the claim text.